Clinical trials: Gene Mutation
Soft-tissue Sarcoma, Triple Negative Breast Cancer
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small…
- Conditions
- Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- Trial name
- NCT07064018
- Testing
- Spedox-6, Pegfilgrastim, Filgrastim
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of California, Irvine
Malignant Melanoma, Brain Metastases
E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
This is a Phase 1 study of E6201 plus dabrafenib for the treatment of CNS metastases in BRAF V600-mutated metastatic melanoma. A total of up to N=28-34 subjects with melanoma metastasized to the CNS will be included.
- Trial name
- NCT03332589
- Testing
- E6201, E6201 plus dabrafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Spirita Oncology, LLC
Opioid Use Disorder
Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
Extended-release buprenorphine (SUBLOCADE®) injection is currently approved for subcutaneous administration in the abdomen for treatment of opioid use disorder (OUD).
- Trial name
- NCT05704543
- Testing
- Buprenorphine Extended-Release Injection
- Where
- 6 sites in United States
- Volunteers
- 132 people
- Sponsor
- Indivior Inc.
Autism Spectrum Disorders
Susceptibility Genes in Autism Spectrum Disorders
The main objective of the study is to define, for Autism Spectrum Disorder, the extent of genetic variation in synaptic pathways that may be targeted for therapeutic development.
- Trial name
- NCT02628808
- Where
- 5 sites in France
- Volunteers
- 1,616 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Carcinoma, Non-Small-Cell Lung
Chemotherapy of NSCLC With or Without Icotinib
Epidermal growth factor receptor (EGFR) mutations occur in up to 50% of Asian patients with non-small cell lung cancer (NSCLC). Treatment of advanced NSCLC patients with EGFR-tyrosine kinase inhibitors (EGFR-TKI) confers a…
- Trial name
- NCT02430974
- Testing
- Icotinib
- Volunteers
- 50 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Metastatic Breast Cancer
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
To assess longitudinal changes in allele frequency of ESR1 mutation in plasma in patients treated with Fulvestrant plus palbociclib compared to tamoxifen plus palbociclib
- Trial name
- NCT02913430
- Testing
- Fulvestrant, Tamoxifen, Palbociclib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Shannon Puhalla
Breast Cancer Susceptibility Gene (BRCA1) Mutation, BRCA2 Mutation
Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene
The goal of this clinical trial is to determine whether an adapted version of a current cognitive-behavioural group therapy (CBT) protocol for cancer survivors to the specific needs of women who are carriers of the BRCA1/2…
- Conditions
- Breast Cancer Susceptibility Gene (BRCA1) Mutation, BRCA2 Mutation, Fear of Cancer Recurrence
- Trial name
- CBT-FCRBRCA1/2 (NCT06817694)
- Testing
- Cognitive-behavioral group therapy
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- CHU de Quebec-Universite Laval
Central Nervous System Neoplasms, Primary
Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS Lymphoma
This study will compare the overall survival (OS) time of elderly patients who would not tolerate standard chemotherapy for PCNSL treated with WBXRT together with Optune-TTF to those treated with whole-brain radiotherapy alone.
- Trial name
- NCT03530605
- Testing
- Optune TTF device
- Sponsor
- Saint Luke's Health System
Mutation, Genetic Syndrome
Screening of Pulmonary Veino Occlusive Disease in Heterozygous EIF2AK4 Mutation Carriers
Pulmonary Veino Occlusive Disease (PVOD) is a rare form of pulmonary arterial hypertension, characterised by a poor prognosis. Recent studies demonstrated that heritable form of pulmonary veino occlusive diseaseis due to…
- Trial name
- DELPHI-4 (NCT03902353)
- Testing
- Screening of adult without diagnosis of PH carrying an heterozygous EIF2AK4 mutation.
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.
- Trial name
- NCT04380753
- Testing
- AMG 510
- Where
- 4 sites in Hong Kong, Taiwan
- Volunteers
- 12 people
- Sponsor
- Amgen
KRAS P.G12C
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001…
- Trial name
- NCT05410145
- Testing
- D3S-001, Pembrolizumab, Cisplatin
- Where
- 52 sites in United States, Australia and 8 more
- Volunteers
- 442 people
- Sponsor
- D3 Bio (Wuxi) Co., Ltd
The Retention of Iodine in Saliva Over the Time, The Comparison of Iodine in Saliva Between Gargle and Swab
Alternative Application Methods of Pre-procedural Povidone Iodine Mouthrinse
To compare the iodine remaining in saliva between gargle method and swab method
- Trial name
- NCT06272019
- Testing
- Iodine gargle
- Where
- Thailand
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Lamin A/C Gene Mutation, Dilated Cardiomyopathy, Familial
The Deep Phenotype of Lamin A/C Cardiomyopathy
This study seeks to discover clinically useful tests to improve the diagnosis of a rare and serious heart muscle disease caused by mutations in a gene called 'Lamin'.
- Trial name
- NCT03860454
- Where
- 6 sites in United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University College, London
Coronary Artery Disease
Alternative Risk Markers in Coronary Artery Disease (ARMCAD)
Estimating the risk of future cardiovascular events such as death, stroke and myocardial infarction using traditional risk factors (such as age, gender, smoking, diabetes, hyperlipidaemia and hypertension) is well accepted in…
- Trial name
- NCT00403351
- Where
- 4 sites in Australia
- Volunteers
- 665 people
- Sponsor
- Monash University
Heart Failure
Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models
This study evaluated the association between sacubitril/valsartan utilization and HF patients' Part A \& B expenditures within the reimbursement framework of BPCI and MSSP, and identified BPCI/MSSP participants with the greatest…
- Trial name
- NCT05096039
- Testing
- Sacubitril/valsartan, ACEI or ARB and no sacubitril/valsartan
- Where
- United States
- Volunteers
- 1,614,719 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer
Based on the existing research results, Osimertinibi is effective not only for patients with sensitizing EGFR mutations, but also for other less common EGFR mutations.
- Trial name
- NCT03460275
- Testing
- Osimertinib Mesylate Tablets
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Locally Advanced or Metastatic NSCLC
Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
To estimate parameters associated with treatment patterns and related clinical outcomes.Including physician reported PFS and OS.
- Trial name
- PISCES (NCT04207775)
- Where
- 16 sites in China
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Pulmonary Alveolar Proteinosis, Mutation Ala393Thr of the MARS Gene
Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.
The purpose of this study is to determine the safety and tolerance of an oral administration of methionine in the treatment of pulmonary alveolar proteinosis due to the double mutation Ala393Thr / Ser567Leu in the MARS gene.
- Conditions
- Pulmonary Alveolar Proteinosis, Mutation Ala393Thr of the MARS Gene, mutationSer567Leu of the MARS Gene
- Trial name
- MetPAP (NCT03887169)
- Testing
- Methionine, Vitamin B12, B9, B6, C supplementation, Methionine/homocysteine Dosage
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer
Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI
Objectives: In this Radboud University Nijmegen Medical Centre (RUNMC) initiated study our first objective is to investigate toxicity (safety and feasibility) of vaccination with frameshift-derived neoantigen-loaded DC of CRC…
- Trial name
- NCT01885702
- Testing
- DC vaccination
- Where
- Netherlands
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Ulcerative Colitis
Trial of Chinese Prescription on Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of the Chinese prescription on Ulcerative Colitis.
- Trial name
- NCT00963287
- Testing
- bascial prescription plus or minus herbs depend on symptoms
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.